Skip to content

Inhibrx Biosciences, Inc. INBX Other current assets

Other current assets at other companies

Pfizer logo
PfizerPFE
Rogers Corporation logo
Rogers CorporationROG
Merck & Co. logo
Merck & Co.MRK
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s other current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s other current assets?
Inhibrx Biosciences, Inc. (INBX) reported other current assets of $262K in Q1 2026.
How has Inhibrx Biosciences, Inc.'s other current assets changed year-over-year?
Inhibrx Biosciences, Inc.'s other current assets decreased by 2.6% year-over-year, from $269K to $262K.
What is the long-term trend for Inhibrx Biosciences, Inc.'s other current assets?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s other current assets has grown at a -19.4% compound annual growth rate (CAGR), from $366K to $238K.